Amylin receptor agonists: A novel pharmacological approach in the management of insulin-treated diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 10, Issue 9, 2001, Pages 1641-1652

  Nyholm, B ^a   Brock, B ^a   Orskov L ^a   Schmitz, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amylin; Beta cell deficiency; Diabetes mellitus; Gastric emptying; Glucagon; Glycaemic control; Insulin; Postprandial hyperglycaemia; Pramlintide

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; AMYLIN RECEPTOR STIMULATING AGENT; AMYLOID; FRUCTOSAMINE; GLUCAGON; GLUCOSE; GLYCOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LOW DENSITY LIPOPROTEIN; PEPTIDE HORMONE; PLACEBO; PRAMLINTIDE; STREPTOZOCIN; SUSTACAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BODY WEIGHT; CLINICAL TRIAL; DISEASE SEVERITY; DOG; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE DEFICIENCY; HORMONE INHIBITION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; POSTPRANDIAL STATE; RAT; REVIEW; RODENT; SATIETY; SIDE EFFECT; STOMACH EMPTYING; STREPTOZOCIN DIABETES; WEIGHT REDUCTION;

AMYLOID; ANIMALS; ANTI-ULCER AGENTS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RECEPTORS, PEPTIDE;

EID: 0034845679     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.9.1641     Document Type: Review

References (100)

1. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans
2. Human islet amyloid polypeptide gene: Complete nucleotide sequence, chromosomal localization, and evolutionary history
3. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
4. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3
5. Amylin concentrations and glucose control
6. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus
7. Islet amyloid and Type 2 diabetes mellitus
8. Polymorphic fibrillar assembly of human amylin
9. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
10. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis
11. Preclinical Pharmacology of pramlintide in the rat: Comparison with human and rat amylin
12. Purification and characterization of a peptide from amyloid-rich pancreases of Type 2 diabetic patients
13. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone
14. Co-secretion of amylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents
15. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls
16. High-frequency oscillations in circulating amylin concentrations in healthy humans
17. Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus
18. Role of islet amyloid polypeptide secretion in insulin-resistant humans
19. Nephrectomy decreases amylin and pramlintide clearance in rats
20. High affinity amylin binding sites in rat brain
21. In vitro autoradiographic localization of amylin binding sites in rat brain
22. Vagal control of digestion: Modulation by central neural and peripheral endocrine factors
23. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve
24. Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells
25. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment
26. The molecular pharmacology of CGRP and related peptide receptor subtypes
27. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product
28. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product
29. Amylin, Islet amyloid polypeptide: Biochemestry, Physiology, Pathophysiology
30. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle
31. Amylin and insulin in rat soleus muscle: Dose responses for cosecreted noncompetitive antagonists
32. Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat
33. Amylin injection causes elevated plasma lactate and glucose in the rat
34. Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats
35. Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver
36. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide
37. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs
38. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle
39. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas
40. Inhibitory effect of islet amyloid polypeptide of glucose-induced proinsulin biosynthesis in rat insulinoma cells
41. Failure of islet amyloid polypeptide to inhibit basal and glucose-stimulated insulin secretion in model experiments in mice and rats
42. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets
43. 8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats
44. Dose-response for glucagonostatic effect of amylin in rats
45. Amylin inhibition of arginine-induced glucagon secretion: Comparison with glucagon-like peptide-1(7-36)-amide (GLP-1)
46. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas
47. Amylin and the gastrointestinal tract
48. Dose-response for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake
49. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
50. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats
51. Amylin inhibits pentagastrin-stimulated gastric acid secretion: Comparison with glucagon-like peptide-1 and exendin-4
52. Amylin inhibits lipase and amylase secretion from the exocrine pancreas in rats
53. Effects of amylin on appetite regulation and memory
54. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin
55. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin
56. Weight gain in male and female mice with amylin gene knockout
57. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man
58. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man
59. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans
60. Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips
61. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes
62. The pathogenesis of insulin-dependent diabetes mellitus
63. Banting lecture 1990. Beta-cells in Type II diabetes mellitus
64. Postprandial Blood Glucose
65. Glucagon and the A cell: Physiology and pathophysiology
66. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy
67. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus
68. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects
69. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus
70. Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects
71. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus
72. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with Type II diabetes mellitus
73. Relationships of upper gastrointestinal motor and sensory function with glycemic control
74. A drug on the market?
75. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue
76. Pramlintide: A human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes
77. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
78. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus
79. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM
80. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: Results of a multicenter trial
81. Effects of 4 week's administration of pramlintide, a human amylin analogue, on glycemic control in patients with IDDM: Effects on plasma glucose profiles and serum fructosamine concentrations
82. The amylin analogue Pramlintide Improves Glycemic Control and Reduces Postprandial Glucagon Concentrations in Patients with Type 1 Diabetes Mellitus
83. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with *type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group
84. Effects of the amylin analogue pramlintide on hepatic glucogen responses and intermediary metabolism in *type 1 diabetic subjects
85. Subcutaneous administration of a human amylin analogue suppresses postprandial glucagon concentrations in Type 1 diabetic patients
86. Amylin modulates insulin secretion in humans. Studies with an amylin agonist
87. Effects of Pramlintide (Amylin Agonist) in Type 1 Diabetes are not mediated by GLP-1 (7-36) amide
88. The Human Amylin Analogue Pramlintide Inhibited Glucagon Secretion in Type 1 Diabetic Subjects
89. Evidence for an important role of changes in rather than absolute concentrations of glucagon in the regulation of glucose production in humans
90. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
91. Role of hyperglucagonamia in maintenance of increased rates of hepatic glucose output in Type II diabetes mellitus
92. Effect of Pramlintide on metabolic control and safety profile in people with Type 1 diabetes
93. Pramlintide therapy in the treatment of insulin-requiring Type 2 diabetes: Results of a 1-year placebo-controlled trial
94. Pramlintide therapy in addition to insulin in type 1 diabetes: Effects on metabolic control after 6 months
95. Pramlintide therapy in addition to insulin in type 2 diabetes: Effects on metabolic control after 6 months
96. Pramlintide as an adjunct to insulin theraphy improves glycemic and weight control in people with Type 1 diabetes during treatment for 52 weeks
97. Pramlintide as an adjunct to insulin theraphy improves glycemic and weight control in people with Type 2 diabetes during treatment for 52 weeks
98. Pramlintide (human amylin analogue) as an adjunct to insulin therapy in patients with Type 1 diabetes improves glycemic control over 2 years
99. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
100. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)